Research Bio
Paul M. Barr, M.D. is an Assistant Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Center.
Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.
He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.
His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.
2013 Feb 6
Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia." Leukemia : official journal of the Leukemia Society of America,
Leukemia Research Fund, U.K. 2013 Feb 6; Epub 2013 Feb 06. |
2013 Feb
Barr PM. "Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials." Oncology (Williston Park, N.Y.). 2013 Feb 0; 27(2):140, 142. |
2012 Jul
Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ. "Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies." Bone marrow transplantation. 2012 Jul 0; 47(7):924-33. Epub 2011 Oct 17. |
2012 Mar
Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW. "Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion." Clinical immunology (Orlando, Fla.). 2012 Mar 0; 142(3):237-42. Epub 2012 Jan 05. |
2012
Caimi PF, Barr PM, Berger NA, Lazarus HM. "Non-Hodgkin's Lymphoma in the Elderly". Drugs & Aging. 2012; 27(3): 211-238. |
